Paxlovid, other COVID-fighting medications more cost-effective than hospitalizations, Montreal study finds
Shortly after Health Canada green-lit the COVID-treating drug Paxlovid, researchers from the Research Institute of the McGill University Health Centre published a study comparing the efficacy and costs of various medications used to combat the virus, including this new addition from Pfizer.
The study found that use of Paxlovid and some other treatments is more cost effective than hospitalization and could reduce the strain on the health network.
Numerous drugs have been repurposed to treat COVID-19 since the pandemic began, from the antidepressant ‘fluvoxamine’ to the gout treatment ‘colchicine.’ But Paxlovid is the first at-home drug designed specifically for the virus to hit the market in Canada. The antiviral medication is prescribed and taken orally, making it a promising treatment against mild-to-moderate cases.
Senior author of the study Dr. Emily McDonald said in a press release that the aim of the research is to help medical professionals determine the most effective and cost efficient approaches to managing COVID-19.
“Available drugs, whether repurposed or new, differ in efficacy, toxicity, cost and complexity of administration. We felt it was important to conduct this study to facilitate comparative decision-making regarding treatment choice,” she said.
The study was published Wednesday in the Oxford journal Open Forum Infectious Diseases.
MONEY SAVERS
When measuring the cost of the drug versus its ability to prevent hospitalization, the study found that Paxlovid, fluvoxamine, colchicine, and inhaled corticosteroids are below the estimated hospitalization cost, which averages at $21,752 per admission.
Paxlovid (Nirmatrelvir-Ritonavir)
Researchers found that Paxlovid is most effective in preventing hospitalizations.
- Prevented hospitalizations: One out of every 24 patients
- Cost per prevented hospitalization: $12,720
Health Canada says a prescription of the medication can be given to anyone over 18 who is at risk of becoming seriously ill from the virus.
Fluvoxamine
Fluvoxamine, on the other hand, averts far fewer hospitalizations but for a fraction of the cost.
- Prevented hospitalizations: One out of every 80 patients
- Cost per prevented hospitalization: $1,122
The drug is sold under the name Luvox and is commonly used to treat obsessive-compulsive disorder and depression.
In a clinical trial ouside from this particular study, some of the same McGill researchers are examining the effects of fluvoxamine more closely. However, Ontario is the only province so far to list the drug as a treatment to be considered for COVID-19 outside of clinical trials.
Colchicine
Colchicine, normally used for the treatment and prevention of gout flare ups, proved to be the least effective medication in the study in terms of reducing hospital admissions.
- Prevented hospitalizations: One out of every 91 patients
- Cost per prevented hospitalization: $3,333
In 2021, a controversial study from the Montreal Heart Institute suggested colchicine was a promising therapeutic approach for COVID-19 patients, but the results of the study and its methodology have since been widely contested.
Inhaled corticosteroids
Inhaled corticosteroids are normally used to treat asthma.
- Prevented hospitalizations: One out of every 72 patients
- Cost per prevented hospitalization: $9,475
PRICIER TREATMENTS
While other antiviral drugs prove to be nearly as effective in curbing hospitalizations as Paxlovid, according to the study, they are frequently more expensive and difficult to obtain.
Remdesivir
Remdesivir, which was originally used to treat Ebola, was approved for use by the Canadian government in July 2020.
- Prevented hospitalizations: One out of every 28 patients
- Cost per prevented hospitalization: $52,416
Sotrovimab
Sotrovimab has a similar success rate to Paxlovid but is far more expensive. The drug was approved for Canada in July 2021.
- Prevented hospitalizations: One of out every 25 patients
- Cost per prevented hospitalization: $52,500
Casirivimab-Imdevimab / Bamlanivimab-Etesevimab
The combination of antibodies casirivimab and imdevimab, as well as the combination of bamlanivimab and etesevimab, are the most expensive treatments on the list and produced the same results in the study.
- Prevented hospitalizations: One of out every 29 patients
- Cost per prevented hospitalization: $60,900
Health Canada okayed the use of casirivimab-imdevimab in June 2021, although the drug is not an effective treatment against the Omicron variant, according to its own manufacturer.
The use of bamlanivimab on its own was approved in Canada in November 2020, but combination of bamlanivimab and etesevimab has yet to be given the thumbs up.
Molnupiravir
Although not yet approved, the medication has been under review by Health Canada since August.
- Prevented hospitalizations: One out of every 50 patients
- Cost per prevented hospitalization: $35,000
EASING THE STRAIN
As Omicron surges across the province and hospitals overflow, drugs such as Paxlovid are looked to as a potential means of easing the burden.
The study authors say that to “prioritize deployment of therapies and capacity building,” health authorities are faced with important decisions regarding which treatments to implement.
“There is an ongoing need to identify effective treatments that can be administered early in the disease to prevent COVID-19 hospitalization and death and to make them available and accessible in all regions,” the study reads.
Quebec is set to receive 6,300 Paxlovid treatments in the near future, although Health Minister Christian Due points out that vaccination is still the province’s “best weapon.”
The province is expected to receive an additional 19,000 treatments in April.
CTVNews.ca Top Stories
MPP Sarah Jama asked to leave Ontario legislature for wearing keffiyeh
MPP Sarah Jama was asked to leave the Legislative Assembly of Ontario by House Speaker Ted Arnott on Thursday for wearing a keffiyeh, a garment which has been banned at Queen’s Park.
Mountain guide dies after falling into a crevasse in Banff National Park
A man who fell into a crevasse while leading a backcountry ski group deep in the Canadian Rockies has died.
2 teens charged in Halifax homicide: police
Two teenagers have been charged with second-degree murder in connection to an alleged homicide near the Halifax Shopping Centre earlier this week.
'Deep ignorance': Calls for Manitoba trustee to resign sparked after comments about Indigenous people and reconciliation
A rural Manitoba school trustee is facing calls to resign over comments he made about Indigenous people and residential schools earlier this week.
12-year-old hippo in Japan raised as a male discovered to be a female
When Gen-chan arrived at a zoo in Japan in 2017, no one questioned whether the then-five-year-old hippopotamus was a boy. Seven years later, zoo staff made a surprising discovery: Gen-chan, now 12, was female.
Here's why Harvey Weinstein's New York rape conviction was tossed and what happens next
Here's what you need to know about why movie mogul Harvey Weinstein's rape conviction was thrown out and what happens next.
Legendary hockey broadcaster Bob Cole dies at 90: CBC
Bob Cole, a welcome voice for Canadian hockey fans for a half-century, has died at the age of 90. Cole died Wednesday night in St. John's, N.L., surrounded by his family, his daughter, Megan Cole, told the CBC.
Humanist group threatening to sue Vancouver over council prayers
The B.C. Humanist Association has threatened legal action against the City of Vancouver for allowing prayers at council, following a similar warning issued earlier this month to a smaller community on Vancouver Island.
LHSC performs a Canadian first in robot-assisted direct lateral spine surgery
Spine surgery may never be the same for people with chronic back pain and other physical ailments.